On Thursday, North American Palladium Ltd (USA) (NYSEMKT:PAL)’s shares declined -47.63% to $ 0.0530.
North American Palladium Ltd (USA) (PAL) declared that, following talk about with Brookfield Capital Partners Ltd. (“Brookfield”), the Company has reached a contract with Brookfield aimed at significantly reducing the Company’s debt and enhancing the Company’s liquidity.
The Company has retained CIBC World Markets Inc. to act as its financial advisor in connection with the Recapitalization and to conduct a planned review process to solicit interest in a sale of the Company. The Company has until June 30, 2015 to obtain a superior proposal to the Recapitalization, with closing to occur within a specified timeframe thereafter.
North American Palladium Ltd. produces precious metals in Canada. It explores for palladium, platinum, gold, nickel, copper, and other metals. It primarily holds interest in the Lac des Iles mine comprising about 8,623 hectares of mineral claims and leases, located to the northwest of Thunder Bay, Ontario.
Carbonite Inc (NASDAQ:CARB)’s shares dropped -5.22% to $10.89.
Carbonite Inc (CARB) declared preliminary financial results for the first quarter ending March 31, 2015, indicating strong bookings and revenue for the period. In addition, the Company declared that its board of directors has concluded its planned alternatives exploration process, which began earlier this year.
Carbonite, Inc. provides cloud and hybrid backup solutions to small and medium sized businesses and individuals in the United States. It offers Carbonite Personal Basic, Carbonite Personal Plus, Carbonite Personal Prime, Carbonite Pro Basic, and Carbonite Pro Prime solutions to access, edit, and share backed-up files from various devices.
At the end of Thursday’s trade, ENSCO PLC (NYSE:ESV)‘s shares dipped -5.19% to $25.20.
ENSCO PLC (ESV) will hold its first quarter 2015 earnings conference call at 10:00 a.m. CDT on Thursday, 30 April 2015. The earnings release will be issued before the New York Stock Exchange opens that morning.
Ensco plc provides offshore contract drilling services to the oil and gas industry worldwide. The company operates through three segments: Floaters, Jackups, and Other. The company owns and operates offshore drilling rig fleet of 70 rigs, counting 10 drillships, 13 semisubmersible rigs, 5 moored semisubmersible rigs, and 42 jackup rigs located in North and South America, the Middle East and Africa, the Asia Pacific rim, Europe and the Mediterranean, and Brazil. It also offers administration services on rigs owned by third-parties.
Celladon Corp (NASDAQ:CLDN), ended its Thursday’s trading session with -4.72% loss, and closed at $17.15.
Celladon Corp (CLDN) declared financial results for the quarter and year ended December 31, 2014 and recent corporate highlights.
Fourth Quarter 2014 and Recent Corporate Highlights
- In February 2015, we reached the last subject’s last visit during the 12 month primary data analysis period in the CUPID2 study, thereby reaching the study’s primary analysis data cutoff. We remain on track to un-blind the data and declare top-line results from this study in late April 2015.
- In December 2014, we commenced work with Novasep, Inc. (Novasep) for the potential future commercial manufacture of MYDICAR drug substance (AAV1/SERCA2a), and in March 2015, we declared the execution of a development, manufacturing and supply contract with Novasep, which, if supported by the CUPID2 data, positions the parties to continue with the process transfer, facility retrofitting, development and manufacturing activities necessary for the future commercial supply of MYDICAR drug substance. If we proceed with the ongoing activities beyond a specified termination period following the un-blinding of CUPID2, we would commit to a multi-year contract for the future commercial supply of MYDICAR drug substance.
- In November 2014, we declared the execution of a facility construction and commercial supply contract with Lonza Biologics, Inc. (Lonza). In exchange for a reservation fee, we have the option, exercisable during a specified timeframe and with further financial obligation, to have Lonza commence construction of a new commercial viral therapeutics manufacturing facility, the exercise of which would commit us to a multi-year contract for the future commercial supply of MYDICAR drug substance.
Celladon Corporation, a clinical-stage biotechnology company, focuses on developing cardiovascular gene therapy and calcium dysregulation. The company’s lead product candidate comprises MYDICAR that uses genetic enzyme replacement therapy to correct the Sarco/endoplasmic reticulum Ca 2+ -ATPase 2a enzyme deficiency in heart failure patients that result in inadequate pumping of the heart. Its MYDICAR product is used to treat patients with systolic heart failure, diastolic heart failure, and advanced heart failure, in addition to to treat pulmonary arterial hypertension and arteriovenous fistula maturation failure.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
